Marina Sievert: Final Debarment Order
FDA issued a 10-year debarment order against Marina Sievert, prohibiting her from importing drugs into the US. This directly impacts med-spas that sourced injectables (e.g., Botox) through her, requiring immediate verification of supply chains.
Aforeworn detected this change in the Med-Spa & Aesthetics Clinics space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Med-spas and aesthetics clinics that purchased or imported drugs (e.g., Botox, dermal fillers) from or through Marina Sievert. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; ongoing compliance required for 10 years.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Med-Spa & Aesthetics Clinics continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Marina Sievert is now debarred from importing any drugs into the US for 10 years. Any drugs she imported or facilitated are now considered adulterated and illegal to distribute or administer.
Who it affects
Med-spas and aesthetics clinics that purchased or imported drugs (e.g., Botox, dermal fillers) from or through Marina Sievert.
What you must do
Immediately identify and quarantine any drugs sourced from Marina Sievert or her associated entities. Verify all injectable inventory against FDA import records and supplier documentation.
Deadline
Immediately; ongoing compliance required for 10 years.
Source: https://www.federalregister.gov/documents/2024/06/06/2024-12356/marina-sievert-final-debarment-order
Never miss a change like this again
Aforeworn watches Med-Spa & Aesthetics Clinics around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Med-Spa & Aesthetics Clinics
- FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
- Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement - FDA Safety Communication
- Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers
- Disruptions in Availability of Breast Biopsy Needles - Letter to Health Care Providers
- UPDATE: Hintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication